In an interview during the 2020 OncLive® State of the Science Summit™ on Advanced Melanoma, Tracey Liebman, MD, assistant professor in the Ronald O. Perelman Department of Dermatology at the NYU…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named…
Occupational therapists and occupational therapy (OT) assistants at NYU Langone Health are finding themselves working on the front line of this pandemic to help patients recover from COVID-19.…
In a retrospective study of patients with single/multilineage bone marrow failure presented at the Virtual Edition of the 25th European Hematology Association Annual Congress, the authors sought to…
Researchers from the National Eye Institute (NEI), with support from the National Institutes of Health (NIH), are analyzing fibrillin-1 mutations to determine the causes of zonule fiber detachment…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
According to findings in an extended follow-up of the ongoing CheckMate 214 trial, nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced…